Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efineptakin alfa - Genexine

Drug Profile

Efineptakin alfa - Genexine

Alternative Names: GX 17; GX-I7; HyLeukin; HyLeukin-7™; IL-7-hyFc; Interleukin-7-hybrid-Fc-recombinant-protein; NT-17; Recombinant human IL-7-hyFc; rhIL-7-hyFc; TJ 107

Latest Information Update: 17 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genexine
  • Developer Genexine; I-MAB Biopharma; Merck & Co; NeoImmuneTech; Roche
  • Class Antineoplastics; Antivirals; Immunoglobulin Fc fragments; Interleukins; Recombinant fusion proteins; Recombinant proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Leucopenia; Idiopathic CD4-positive T-lymphocytopenia
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Breast cancer; Glioblastoma; Solid tumours
  • Phase I Cervical intraepithelial neoplasia; Human papillomavirus infections; Leucopenia; Skin cancer
  • Preclinical Lymphoma

Most Recent Events

  • 12 Dec 2019 NeoImmuneTech entered into a clinical collaboration agreement with Merck Sharp and Dohme for basket study in patients with Solid tumours
  • 10 Dec 2019 NeoImmuneTech in collaboration with Merck Sharp & Dohme plans a phase Ib/2a basket trial in Solid tumours (Second-line therapy of greater, Combination therapy)
  • 28 Aug 2019 No recent reports of development identified for phase-I development in Human-papillomavirus-infections in South Korea (SC, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top